Medline walked into this earnings season priced for perfection with a rich 46.4x P/E and a reputation as a steady healthcare supplier. The stock then dropped almost 13% in a single session, wiping away weeks of gains. That move came after a quarter in which revenue reached about US$7.7b and adjusted EBITDA touched roughly US$1.06b. However, investors fixated on a thinner net income line and the squeeze on margins.

For you as a shareholder, the story today is not about sales growth. It is about whether this profit pressure is a temporary bruise or a more persistent earnings strain on Medline.

Is Medline’s 46.4x P/E simply too rich for a stock with 2.3% trailing net margins and thinner recent earnings, or is the market missing something in this setup? Compare current price, growth assumptions and margin risk against our valuation analysis for Medline

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$7,685m vs. US$6,886m (up about 11.6%)
• Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$60m vs. US$333m (down about 82%)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.070011 vs. US$0.019026 (up about 268%)
• Adjusted EBITDA (Q2 2026 vs Q2 2025): US$1.06b vs. prior year Q2 level not specified (reported margin 13.8%, including a US$243m IEEPA tariff refund benefit; underlying adjusted EBITDA about US$817m)

Prefer clean, visual charts instead of scrolling through dense earnings tables and margin figures for Medline? See the company’s full financial picture, including a clear view of its valuation, in our company report for Medline.

Medline bull case meets real operating tests

Bulls argue Medline is building a higher quality, more efficient growth engine through automation, Prime Vendor wins and supply chain expansion. Q2 backs some of that up. Net sales rose about 12% to US$7.7b and management lifted full year organic growth guidance to a range of 9% to 10%, helped by Supply Chain Solutions at US$4.1b with 16% growth and Medline Brand at US$3.5b with 7% growth despite retail pressure. Prime Vendor traction looks real, with more than US$650m of new customer signings in the first half, already around 65% of the US$1b full year goal. Automation and capacity projects are progressing, including more AutoStore deployments and a larger California footprint after the Tracy fire. However, the need to cut adjusted EBITDA guidance to US$3.3–3.4b shows efficiency gains are not yet offsetting higher input costs and quality and investment spend.

Margin reset and regulatory overhang fuel bear worries

Bears focus on thin profitability, execution risk on big projects and regulatory and legal exposure. Q2 offers some clear support for those concerns. Net income excluding extra items fell sharply to US$60m against US$333m a year ago, despite the IEEPA tariff refund that lifted reported adjusted EBITDA to US$1.06b. Underlying adjusted EBITDA of about US$817m plus the cut to full year EBITDA guidance signal a more expensive cost base from fuel, inputs, quality remediation and California distribution rebuilds. Management expects roughly half of the incremental cost impact to be ongoing, which points to a structurally lower margin starting point. The FDA warning letter and related securities investigation remain unresolved and management flagged higher Medical Device Reports and remediation expenses in the second half of 2026. The stock’s near 13% one day drop and weaker 30 day and 90 day returns show these risks are front and center for investors.

Compare Medline’s push on automation, Prime Vendor wins and capacity upgrades with the sharp margin reset to see whether analysts expect these internal moves to rebuild confidence or keep pressure on the stock. See the consensus price target analysis for Medline

Take Control of Your Medline Thesis

If Medline’s sharp margin reset and rich 46.4x P/E have your attention, register for free with Simply Wall St and add it to a Watchlist to track how the share price lines up against fair value before deciding on an entry point. Once you decide to own Medline, use the Portfolio Command Center to keep your holdings organised and filter out noise so you only see the most important changes to its earnings, margins and risks. For a broader view on sentiment around Medline and similar stocks, tap into thousands of investor perspectives through the Community. By surfacing potential catalysts and warning signs early, Simply Wall St helps you act with confidence and stay ahead of the market.

Seeking Alternatives Beyond Medline?

Fresh ideas do not stay under the radar for long. Some stocks are building quiet momentum while others risk getting caught dropping before the crowd reacts. Act now and get in early.

• Spot companies with strong balance sheets before momentum really starts to build by scanning our curated list of solid balance sheet and fundamentals stocks (50 results) so you are not chasing moves after they are flying.
• Target resilient income opportunities by reviewing hand picked 8 dividend fortresses while yields and prices still look aligned and before a broad rush compresses those payouts.
• Zero in on stocks with lower risk profiles using a focused set of 79 resilient stocks with low risk scores so you can respond while pricing still reflects under the radar caution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.